Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|June 4, 2005

UCLA researchers use F-18 FDDNP to visualize beta-amyloid load in vivo

Author(s)James Brice

CONTEXT: Neurotoxic beta-amyloid accumulates in regions of the brain affected by advanced Alzheimer's disease. It is a suspected contributor to the development of the condition.

RESULTS: Dr. Jorge Barrio and researchers from the University of California, Los Angeles demonstrated that F-18 FDDNP microPET can visualize b-amyloid load in vivo in the brains of transgenic mice. Dynamic scans with the agent were performed on three experimental and two control animals. FDDNP uptake was elevated in the cerebral cortex, most prominently in the frontal lobe and hippocampal regions of the experimental transgenic mice (p = 0.001). Only background cortical binding was seen in control subjects. Results were consistent with previous in vitro results with b-amyloid neurofibrils and brain specimens of Alzheimer's disease patients. They were presented at the 2005 Academy of Molecular Imaging meeting.

IMPLICATIONS: The ability to quantify beta-amyloid plaque load could identify healthy adults who are suspicious for the future development of AD and could play a role in monitoring the effect of anti-amyloid therapies.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.